Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities

References

• Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011 May 10;7(6):332–342.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Guan Y, Ramanathan M, et al. Lifestyle-based modifiable risk factors in multiple sclerosis: review of preclinical and clinical findings neurodegener. Dis Manag. 2019.
   Google Scholar
• Cree BA, Gourraud PA, Oksenberg, J.R, et al.; University of California SFMSET. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct;80(4):499–510.
   PubMed Web of Science ®Google Scholar
• Rotstein DL, Chen H, Wilton AS, et al. Temporal trends in multiple sclerosis prevalence and incidence in a large population. Neurology. 2018 Apr 17;90(16):e1435–e1441.
   PubMed Web of Science ®Google Scholar
• Grytten N, Aarseth JH, Lunde HM, et al. A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):100–105.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Yu N, Blanchard J, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010 Feb 9;74(6):465–471.
   PubMed Web of Science ®Google Scholar
• Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017 Jun;13(6):375–382.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Yu BN, Leung S, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler. 2012 Sep;18(9):1310–1319.
   PubMed Web of Science ®Google Scholar
• Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler. 2013 Sep;19(10):1336–1340.
   PubMed Web of Science ®Google Scholar
• Christiansen CF, Christensen S, Farkas DK, et al. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology. 2010;35(4):267–274.
   PubMed Web of Science ®Google Scholar
• Thormann A, Magyari M, Koch-Henriksen N, et al. Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. J Neurol. 2016 Dec;263(12):2484–2493.
   PubMed Web of Science ®Google Scholar
• Allen NB, Lichtman JH, Cohen HW, et al. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology. 2008;30(4):234–238.
   PubMed Web of Science ®Google Scholar
• Amato MP, Derfuss T, Hemmer B, et al. Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult Scler. 2017;6:1352458516686847.
   Google Scholar
• Pinhas-Hamiel O, Livne M, Harari G, et al. Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability. Eur J Neurol. 2015 Sep;22(9):1275–1279.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186–1191.
   PubMed Web of Science ®Google Scholar
• Saroufim P, Zweig SA, Conway DS, et al. Cardiovascular conditions in persons with multiple sclerosis, neuromyelitis optica and transverse myelitis. Mult Scler Relat Disord. 2018;25:21–25.
   PubMed Web of Science ®Google Scholar
• Marrosu MG, Cocco E, Lai M, et al. Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet. 2002 Apr 27;359(9316):1461–1465.
   PubMed Web of Science ®Google Scholar
• Conway DS, Thompson NR, Cohen JA. Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course. Mult Scler. 2017 Feb;23(2):277–285.
   PubMed Web of Science ®Google Scholar
• Zhang T, Tremlett H, Zhu F, et al. Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology. 2018 Jan 30;90(5):e419–e427.
   PubMed Web of Science ®Google Scholar
• Kowalec K, McKay KA, Patten SB, et al. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. Neurology. 2017 Dec 12;89(24):2455–2461.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Horwitz R, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009 Jan 13;72(2):117–124.
   PubMed Web of Science ®Google Scholar
• Thormann A, Sorensen PS, Koch-Henriksen N, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017 Oct 17;89(16):1668–1675.
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 Aug 4;370(9585):389–397.
   PubMed Web of Science ®Google Scholar
• Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016 Apr 5;86(14):1287–1295.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015 Jul 21;85(3):240–247.
   PubMed Web of Science ®Google Scholar
• Kvistad SS, Myhr KM, Holmoy T, et al. Body mass index influence interferon-beta treatment response in multiple sclerosis. J Neuroimmunol. 2015 Nov;15(288):92–97.
   Web of Science ®Google Scholar
• Petersen ER, Oturai AB, Koch-Henriksen N, et al. Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology. 2018 Feb 13;90(7):e593–e600.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009 Aug 18;73(7):504–510.
   PubMed Web of Science ®Google Scholar
• Petersen ER, Sondergaard HB, Laursen JH, et al. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler. 2018;2:1352458518791753.
   Google Scholar
• Ranadive SM, Yan H, Weikert M, et al. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc. 2012 Feb;44(2):238–243.
   PubMed Web of Science ®Google Scholar
• Maillard P, Seshadri S, Beiser A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham heart study: a cross-sectional study. Lancet Neurol. 2012 Dec;11(12):1039–1047.
   PubMed Web of Science ®Google Scholar
• Srinivasa RN, Rossetti HC, Gupta MK, et al. Cardiovascular risk factors associated with smaller brain volumes in regions identified as early predictors of cognitive decline. Radiology. 2016 Jan;278(1):198–204.
   PubMed Web of Science ®Google Scholar
• Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul;66(7):858–864.
   PubMed Web of Science ®Google Scholar
• Horakova D, Zivadinov R, Weinstock-Guttman B, et al. Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One. 2013;8(1):e53996.
   PubMed Web of Science ®Google Scholar
• Kappus N, Weinstock-Guttman B, Hagemeier J, et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):181–187.
   PubMed Web of Science ®Google Scholar
• Pichler A, Khalil M, Langkammer C, et al. The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis. Mult Scler. 2017;1:1352458517736149.
   Google Scholar
• Jakimovski D, Gandhi S, Paunkoski I, et al. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. Eur J Neurol. 2019 Jan;26(1):87–e8.
   PubMed Web of Science ®Google Scholar
• Lorefice L, Frau J, Coghe G, et al. Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study. Mult Scler Relat Disord. 2019;27:74–78.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Weinstock-Guttman B, Gandhi S, et al. Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. J Neurol. 2019.
   PubMed Web of Science ®Google Scholar
• Dossi DE, Chaves H, Heck ES, et al. Effects of systolic blood pressure on brain integrity in multiple sclerosis. Front Neurol. 2018;9:487.
   PubMed Web of Science ®Google Scholar
• Lycke J, Wikkelso C, Bergh AC, et al. Regional cerebral blood flow in multiple sclerosis measured by single photon emission tomography with technetium-99m hexamethylpropyleneamine oxime. Eur Neurol. 1993;33(2):163–167.
   PubMedGoogle Scholar
• Bakshi R, Miletich RS, Kinkel PR, et al. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging. 1998;8(4):228–234.
   PubMed Web of Science ®Google Scholar
• Sun X, Tanaka M, Kondo S, et al. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med. 1998 Apr;12(2):89–94.
   PubMedGoogle Scholar
• Derache N, Marie RM, Constans JM, et al. Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: correlations to lesion load. J Neurol Sci. 2006 Jun 15;245(1–2):103–109.
   PubMed Web of Science ®Google Scholar
• Hogel H, Rissanen E, Vuorimaa A, et al. Positron emission tomography imaging in evaluation of MS pathology in vivo. Mult Scler. 2018 Oct;24(11):1399–1412.
   PubMed Web of Science ®Google Scholar
• MacDonald ME, Frayne R. Cerebrovascular MRI: a review of state-of-the-art approaches, methods and techniques. NMR Biomed. 2015 Jul;28(7):767–791.
   PubMed Web of Science ®Google Scholar
• Rashid W, Parkes LM, Ingle GT, et al. Abnormalities of cerebral perfusion in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1288–1293.
   PubMed Web of Science ®Google Scholar
• Inglese M, Adhya S, Johnson G, et al. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab. 2008 Jan;28(1):164–171.
   PubMed Web of Science ®Google Scholar
• Amann M, Achtnichts L, Hirsch JG, et al. 3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. Mult Scler. 2012 Nov;18(11):1570–1576.
   PubMed Web of Science ®Google Scholar
• Ingrisch M, Sourbron S, Morhard D, et al. Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T. Invest Radiol. 2012 Apr;47(4):252–258.
   PubMed Web of Science ®Google Scholar
• Aviv RI, Francis PL, Tenenbein R, et al. Decreased frontal lobe gray matter perfusion in cognitively impaired patients with secondary-progressive multiple sclerosis detected by the bookend technique. AJNR Am J Neuroradiol. 2012 Oct;33(9):1779–1785.
   PubMed Web of Science ®Google Scholar
• D‘Haeseleer M, Steen C, Hoogduin JM, et al. Performance on paced auditory serial addition test and cerebral blood flow in multiple sclerosis. Acta Neurol Scand. 2013 Nov;128(5):e26–9.
   PubMed Web of Science ®Google Scholar
• Steen C, D‘Haeseleer M, Hoogduin JM, et al. Cerebral white matter blood flow and energy metabolism in multiple sclerosis. Mult Scler. 2013 Sep;19(10):1282–1289.
   PubMed Web of Science ®Google Scholar
• Debernard L, Melzer TR, Van Stockum S, et al. Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014 May;85(5):544–551.
   PubMed Web of Science ®Google Scholar
• Li L, Chopp M, Nejad-Davarani SP, et al. Perfusion and diffusion abnormalities of multiple sclerosis lesions and relevance of classified lesions to disease status. J Neurol Neurophysiol. 2014 Apr;2014(Suppl 12):12.
   PubMedGoogle Scholar
• Papadaki EZ, Simos PG, Mastorodemos VC, et al. Regional MRI perfusion measures predict motor/executive function in patients with clinically isolated syndrome. Behav Neurol. 2014;2014:252419.
   PubMedGoogle Scholar
• Sowa P, Bjornerud A, Nygaard GO, et al. Reduced perfusion in white matter lesions in multiple sclerosis. Eur J Radiol. 2015 Dec;84(12):2605–2612.
   PubMed Web of Science ®Google Scholar
• Fan AP, Govindarajan ST, Kinkel RP, et al. Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis. J Cereb Blood Flow Metab. 2015 Jan;35(1):131–139.
   PubMed Web of Science ®Google Scholar
• Hojjat SP, Cantrell CG, Carroll TJ, et al. Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patients. Mult Scler. 2016 Nov;22(13):1685–1694.
   PubMed Web of Science ®Google Scholar
• Hojjat SP, Kincal M, Vitorino R, et al. Cortical perfusion alteration in normal-appearing gray matter is most sensitive to disease progression in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2016 Aug;37(8):1454–1461.
   PubMed Web of Science ®Google Scholar
• Doche E, Lecocq A, Maarouf A, et al. Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis. J Neuroradiol. 2017 Mar;44(2):158–164.
   PubMed Web of Science ®Google Scholar
• Ingrisch M, Sourbron S, Herberich S, et al. Dynamic contrast-enhanced magnetic resonance imaging suggests normal perfusion in normal-appearing white matter in multiple sclerosis. Invest Radiol. 2017 Mar;52(3):135–141.
   PubMed Web of Science ®Google Scholar
• Sowa P, Nygaard GO, Bjornerud A, et al. Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis. Neuroradiology. 2017 Jul;59(7):655–664.
   PubMed Web of Science ®Google Scholar
• Lagana MM, Mendozzi L, Pelizzari L, et al. Are cerebral perfusion and atrophy linked in multiple sclerosis? Evidence for a multifactorial approach to assess neurodegeneration. Curr Neurovasc Res. 2018;15(4):282 – 291.
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo X, Zhang N, et al. Cerebral blood flow changes in multiple sclerosis and neuromyelitis optica and their correlations with clinical disability. Front Neurol. 2018;9:305.
   PubMed Web of Science ®Google Scholar
• Law M, Saindane AM, Ge Y, et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology. 2004 Jun;231(3):645–652.
   PubMed Web of Science ®Google Scholar
• Papadaki EZ, Mastorodemos VC, Amanakis EZ, et al. White matter and deep gray matter hemodynamic changes in multiple sclerosis patients with clinically isolated syndrome. Magn Reson Med. 2012 Dec;68(6):1932–1942.
   PubMed Web of Science ®Google Scholar
• Adhya S, Johnson G, Herbert J, et al. Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage. 2006 Dec;33(4):1029–1035.
   PubMed Web of Science ®Google Scholar
• Mulholland AD, Vitorino R, Hojjat SP, et al. Spatial correlation of pathology and perfusion changes within the cortex and white matter in multiple sclerosis. AJNR Am J Neuroradiol. 2018 Jan;39(1):91–96.
   PubMed Web of Science ®Google Scholar
• Vitorino R, Hojjat SP, Cantrell CG, et al. Regional frontal perfusion deficits in relapsing-remitting multiple sclerosis with cognitive decline. AJNR Am J Neuroradiol. 2016 Oct;37(10):1800–1807.
   PubMed Web of Science ®Google Scholar
• Hojjat SP, Cantrell CG, Vitorino R, et al. Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients. Mult Scler. 2016 Oct;22(11):1421–1428.
   PubMed Web of Science ®Google Scholar
• Ota M, Sato N, Nakata Y, et al. Abnormalities of cerebral blood flow in multiple sclerosis: a pseudocontinuous arterial spin labeling MRI study. Magn Reson Imaging. 2013 Jul;31(6):990–995.
   PubMed Web of Science ®Google Scholar
• Francis PL, Jakubovic R, O‘Connor P, et al. Robust perfusion deficits in cognitively impaired patients with secondary-progressive multiple sclerosis. AJNR Am J Neuroradiol. 2013 Jan;34(1):62–67.
   PubMed Web of Science ®Google Scholar
• Varga AW, Johnson G, Babb JS, et al. White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci. 2009 Jul 15;282(1–2):28–33.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Weinstock-Guttman B, Hagemeier J, et al. Walking disability measures in multiple sclerosis patients: correlations with MRI-derived global and microstructural damage. J Neurol Sci. 2018 Oct;15(393):128–134.
   Google Scholar
• Lin F, Zivadinov R, Hagemeier J, et al. Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. Mult Scler. 2018 Jul 1:1352458518788218.
   Google Scholar
• Inglese M, Park SJ, Johnson G, et al. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol. 2007 Feb;64(2):196–202.
   PubMedGoogle Scholar
• Wuerfel J, Bellmann-Strobl J, Brunecker P, et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain. 2004 Jan;127(Pt 1):111–119.
   PubMedGoogle Scholar
• Ge Y, Law M, Johnson G, et al. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1539–1547.
   PubMed Web of Science ®Google Scholar
• Peruzzo D, Castellaro M, Calabrese M, et al. Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study. J Cereb Blood Flow Metab. 2013 Mar;33(3):457–463.
   PubMed Web of Science ®Google Scholar
• Dury RJ, Falah Y, Gowland PA, et al. Ultra-high-field arterial spin labelling MRI for non-contrast assessment of cortical lesion perfusion in multiple sclerosis. Eur Radiol. 2019;29(4):2027–2033.
   PubMed Web of Science ®Google Scholar
• Holland CM, Charil A, Csapo I, et al. The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging. 2012 Apr;22(2):129–136.
   PubMed Web of Science ®Google Scholar
• Narayana PA, Zhou Y, Hasan KM, et al. Hypoperfusion and T1-hypointense lesions in white matter in multiple sclerosis. Mult Scler. 2014 Mar;20(3):365–373.
   PubMed Web of Science ®Google Scholar
• Haider L, Zrzavy T, Hametner S, et al. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain. 2016 Mar;139(Pt 3):807–815.
   PubMedGoogle Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015 Feb;14(2):183–193.
   PubMed Web of Science ®Google Scholar
• Ma AY, Vitorino RC, Hojjat SP, et al. The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis. Mult Scler. 2017 Dec;23(14):1884–1892.
   PubMed Web of Science ®Google Scholar
• Saindane AM, Law M, Ge Y, et al. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol. 2007 Apr;28(4):767–772.
   PubMed Web of Science ®Google Scholar
• Thomalla G, Glauche V, Weiller C, et al. Time course of wallerian degeneration after ischaemic stroke revealed by diffusion tensor imaging. J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):266–268.
   PubMed Web of Science ®Google Scholar
• Davies AL, Desai RA, Bloomfield PS, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol. 2013 Dec;74(6):815–825.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415.
   PubMed Web of Science ®Google Scholar
• D‘Haeseleer M, Beelen R, Fierens Y, et al. Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5654–5658.
   PubMed Web of Science ®Google Scholar
• Laureys G, Clinckers R, Gerlo S, et al. Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog Neurobiol. 2010 Jul;91(3):189–199.
   PubMed Web of Science ®Google Scholar
• De Keyser J, Zeinstra E, Wilczak N. Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol Dis. 2004 Mar;15(2):331–339.
   PubMed Web of Science ®Google Scholar
• De Keyser J, Wilczak N, Leta R, et al. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology. 1999 Nov 10;53(8):1628–1633.
   PubMed Web of Science ®Google Scholar
• Itoh N, Itoh Y, Tassoni A, et al. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: focus on astrocytes. Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E302–E309.
   PubMed Web of Science ®Google Scholar
• Petzold GC, Murthy VN. Role of astrocytes in neurovascular coupling. Neuron. 2011 Sep 8;71(5):782–797.
   PubMed Web of Science ®Google Scholar
• Dutta DJ, Woo DH, Lee PR, et al. Regulation of myelin structure and conduction velocity by perinodal astrocytes. Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):11832–11837.
   PubMed Web of Science ®Google Scholar
• Durfinova M, Bartova R, Prochazkova L, et al. Role of astrocytes in pathogenesis of multiple sclerosis and their participation in regulation of cerebral circulation. Neuro Endocrinol Lett. 2014;35(8):666–672.
   PubMed Web of Science ®Google Scholar
• Pelletier S, Battistini B, Sirois P. Adenosine-induced inhibition of basal endothelin-1 production from guinea-pig tracheal epithelial cells: a mechanism involving the release of cAMP. Pulm Pharmacol Ther. 1998 Apr-Jun;11(2–3):237–242.
   PubMed Web of Science ®Google Scholar
• D‘Haeseleer M, Hostenbach S, Peeters I, et al. Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis? J Cereb Blood Flow Metab. 2015 Sep;35(9):1406–1410.
   PubMed Web of Science ®Google Scholar
• Lecrux C, Hamel E. The neurovascular unit in brain function and disease. Acta Physiol (Oxf). 2011 Sep;203(1):47–59.
   PubMed Web of Science ®Google Scholar
• Marshall O, Lu H, Brisset JC, et al. Impaired cerebrovascular reactivity in multiple sclerosis. JAMA Neurol. 2014 Oct;71(10):1275–1281.
   PubMed Web of Science ®Google Scholar
• Marshall O, Chawla S, Lu H, et al. Cerebral blood flow modulation insufficiency in brain networks in multiple sclerosis: A hypercapnia MRI study. J Cereb Blood Flow Metab. 2016 Dec;36(12):2087–2095.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002 Aug;1(4):232–241.
   PubMed Web of Science ®Google Scholar
• Metzger A, Le Bars E, Deverdun J, et al. Is impaired cerebral vasoreactivity an early marker of cognitive decline in multiple sclerosis patients? Eur Radiol. 2018 Mar;28(3):1204–1214.
   PubMed Web of Science ®Google Scholar
• Chung CC, Pimentel D, Jor‘Dan AJ, et al. Inflammation-associated declines in cerebral vasoreactivity and cognition in type 2 diabetes. Neurology. 2015 Aug 4;85(5):450–458.
   PubMed Web of Science ®Google Scholar
• Richiardi J, Monsch AU, Haas T, et al. Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer‘s disease. Neurobiol Aging. 2015 Jan;36(1):33–41.
   PubMed Web of Science ®Google Scholar
• Stickland R, Allen M, Magazzini L, et al. Neurovascular coupling during visual stimulation in multiple sclerosis: a MEG-fMRI study. Neuroscience. 2019;403:54–69.
   PubMed Web of Science ®Google Scholar
• Uzuner N, Ozkan S, Cinar N. Cerebrovascular reactivity in multiple sclerosis patients. Mult Scler. 2007 Jul;13(6):737–741.
   PubMedGoogle Scholar
• Tekgol Uzuner G, Uzuner N. Neurovascular coupling in patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg. 2016 Jul;146:24–28.
   PubMed Web of Science ®Google Scholar
• Belov P, Jakimovski D, Krawiecki J, et al. Lower arterial cross-sectional area of carotid and vertebral arteries and higher frequency of secondary neck vessels are associated with multiple sclerosis. AJNR Am J Neuroradiol. 2018 Jan;39(1):123–130.
   PubMed Web of Science ®Google Scholar
• Yuksel B, Koc B, Kurtulus F, et al. Is multiple sclerosis a risk factor for atherosclerosis? In Multiple Sclerosis Journal. 2016;22:455–455).
   Google Scholar
• Pelizzari L, Lagana MM, Jakimovski D, et al. Neck vessel cross-sectional area measured with MRI: scan-rescan reproducibility for longitudinal evaluations. J Neuroimaging. 2018 Jan;28(1):48–56.
   PubMed Web of Science ®Google Scholar
• Pelizzari L, Jakimovski D, Lagana MM, et al. Five-year longitudinal study of neck vessel cross-sectional area in multiple sclerosis. AJNR Am J Neuroradiol. 2018 Sep;39(9):1703–1709.
   PubMed Web of Science ®Google Scholar
• Kammertoens T, Friese C, Arina A, et al. Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature. 2017 May 4;545(7652):98–102.
   PubMed Web of Science ®Google Scholar
• van Langelaar J, van der Vuurst de Vries RM, Janssen M, et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain. 2018 May 1;141(5):1334–1349.
   PubMedGoogle Scholar
• la Sala A, Pontecorvo L, Agresta A, et al. Regulation of collateral blood vessel development by the innate and adaptive immune system. Trends Mol Med. 2012 Aug;18(8):494–501.
   PubMed Web of Science ®Google Scholar
• Chen L, Huang J, Wang S, et al. Effect of carotid artery morphological variations on cognitive function. Behav Neurol. 2018;2018:7290431.
   PubMedGoogle Scholar
• Jakimovski D, Benedict R, Marr K, et al. Lower total cerebral arterial flow contributes to cognitive perofrmance in multiple sclerosis patients. Mult Scler. 2018. https://doi.org/10.1177/1352458518819608.
   PubMedGoogle Scholar
• Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):392–399.
   PubMed Web of Science ®Google Scholar
• Liu M, Xu H, Wang Y, et al. Patterns of chronic venous insufficiency in the dural sinuses and extracranial draining veins and their relationship with white matter hyperintensities for patients with Parkinson‘s disease. J Vasc Surg. 2015 Jun;61(6):1511–20 e1.
   PubMed Web of Science ®Google Scholar
• Di Berardino F, Alpini DC, Bavera PM, et al. Chronic cerebrospinal venous insufficiency in meniere disease. Phlebology. 2015 May;30(4):274–279.
   PubMed Web of Science ®Google Scholar
• Alpini D, Bavera PM, Di Berardino F, et al. Bilateral sudden sensorineural hearing loss and chronic venous cerebrospinal insufficiency: a case report. Phlebology. 2013 Aug;28(5):231–233.
   PubMed Web of Science ®Google Scholar
• Baracchini C, Perini P, Calabrese M, et al. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol. 2011 Jan;69(1):90–99.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Marr K, Cutter G, et al. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology. 2011 Jul 12;77(2):138–144.
   PubMed Web of Science ®Google Scholar
• Dolic K, Marr K, Valnarov V, et al. Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Funct Neurol. 2011 Oct-Dec;26(4):205–214.
   PubMed Web of Science ®Google Scholar
• Caprio MG, Marr K, Gandhi S, et al. Centralized and local color doppler ultrasound reading agreement for diagnosis of the chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. Curr Neurovasc Res. 2017 Jul 17;14(3):266–273.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Bastianello S, Dake MD, et al. Recommendations for multimodal noninvasive and invasive screening for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency: a position statement of the International Society for Neurovascular Disease. J Vasc Interv Radiol. 2014 Nov;25(11):1785–94 e17.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Marr K, Zivadinov R. Imaging of extracranial obstructive venous disease. Ital J Vasc Endovasc Surg. 2018;25(2):176–89.
   Web of Science ®Google Scholar
• Zamboni P, Galeotti R, Menegatti E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg. 2009 Dec;50(6):1348–58e1–3.
   Web of Science ®Google Scholar
• Siddiqui AH, Zivadinov R, Benedict RH, et al. Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology. 2014 Jul 29;83(5):441–449.
   PubMed Web of Science ®Google Scholar
• Zamboni P, Tesio L, Galimberti S, et al. Efficacy and safety of extracranial vein angioplasty in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2018 Jan 1;75(1):35–43.
   PubMed Web of Science ®Google Scholar
• Traboulsee AL, Machan L, Girard JM, et al. Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial. Neurology. 2018 Oct 30;91(18):e1660–e1668.
   PubMed Web of Science ®Google Scholar
• Zamboni P, Zivadinov R. Extracranial veins in multiple sclerosis: is there a role for vascular surgery? Eur J Vasc Endovasc Surg. 2018 Nov;56(5):618–621.
   PubMedGoogle Scholar
• Zivadinov R, Weinstock-Guttman B. Multiple sclerosis: extracranial venous angioplasty is ineffective to treat MS. Nat Rev Neurol. 2018 Mar;14(3):129–130.
   PubMed Web of Science ®Google Scholar
• Power MC, Mormino E, Soldan A, et al. Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol. 2018;84:10–22.
   Web of Science ®Google Scholar
• Roy S, Drake A, Snyder S, et al. Preliminary investigation of cognitive function in aged multiple sclerosis patients: challenges in detecting comorbid Alzheimer‘s disease. Mult Scler Relat Disord. 2018 Mar;13(22):52–56.
   Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009 May;132(Pt 5):1175–1189.
   PubMed Web of Science ®Google Scholar
• Knutsson L, Stahlberg F, Wirestam R. Absolute quantification of perfusion using dynamic susceptibility contrast MRI: pitfalls and possibilities. Magma. 2010 Feb;23(1):1–21.
   PubMedGoogle Scholar
• Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2015 Jan;73(1):102–116.
   PubMed Web of Science ®Google Scholar
• Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2019.
   PubMedGoogle Scholar
• Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015 Jan 21;85(2):296–302.
   PubMed Web of Science ®Google Scholar
• Leech S, Kirk J, Plumb J, et al. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol. 2007 Feb;33(1):86–98.
   PubMed Web of Science ®Google Scholar
• Ziliotto N, Bernardi F, Jakimovski D, et al. Coagulation pathways in neurological diseases: multiple sclerosis. Front Neurol. 2019;10: P. 409 ISSN=1664–2295.
   PubMed Web of Science ®Google Scholar
• Ryu JK, Petersen MA, Murray SG, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. 2015 Sep;10(6):8164.
   Google Scholar
• Ryu JK, Rafalski VA, Meyer-Franke A, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol. 2018 Oct 15.
   Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul 16;523(7560):337–341.
   PubMed Web of Science ®Google Scholar
• Louveau A, Da Mesquita S, Kipnis J. Lymphatics in neurological disorders: a neuro-lympho-vascular component of multiple sclerosis and Alzheimer‘s disease? Neuron. 2016 Sep 7;91(5):957–973.
   PubMed Web of Science ®Google Scholar